Luspatercept-aamt (Reblozyl)

Reblozyl (luspatercept‑aamt) is covered only for anemia in adults (≥18) with beta thalassemia who require regular RBC transfusions (including transfusion‑dependent patients); other/non‑FDA indications are not covered. Coverage requires hematologist prescription/consultation, documentation of diagnosis and transfusion history, adherence to label dosing (start 1 mg/kg SC q3w), initial authorization of 4 months and 12‑month renewals contingent on a clinically meaningful reduction in transfusion burden.

"Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.